...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Biogen looks to FDA for approval of early Alzheimers drug.

CitySlicker99,

The only info that has been released is that BETonMACE did not meet the primary endpoint. We have zero info on whether the lack of statistical significance was a near miss (p=0.06) or total miss (really bad p-value). We have zero details on the 3-point MACE breakdown (#CVD deaths, non-fatal MI, non-fatal stroke). We have zero information on the CKD or cognition sub-studies. And we have zero information on the numerous secondary endpoints, including the ones you brought up. 

BDAZ

Share
New Message
Please login to post a reply